Abeona Therapeutics Inc. (ABEO) Given a $14.00 Price Target at Maxim Group
Maxim Group set a $14.00 price target on Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research report report published on Wednesday morning. The firm currently has a a buy rating on the biopharmaceutical company’s stock.
Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald reissued a buy rating and set a $21.00 target price on shares of Abeona Therapeutics in a research note on Friday, September 30th. FBR & Co set a $15.00 price target on Abeona Therapeutics and gave the stock a buy rating in a research note on Wednesday, September 21st. Zacks Investment Research cut Abeona Therapeutics from a hold rating to a sell rating in a research note on Monday, September 12th. Finally, Rodman & Renshaw reaffirmed a buy rating and issued a $17.00 price target on shares of Abeona Therapeutics in a research note on Sunday, August 21st. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $14.50.
Abeona Therapeutics (NASDAQ:ABEO) traded down 5.3827% during midday trading on Wednesday, hitting $6.3299. The stock had a trading volume of 199,777 shares. Abeona Therapeutics has a 52 week low of $2.05 and a 52 week high of $7.00. The firm’s market cap is $212.34 million. The firm has a 50 day moving average of $5.08 and a 200 day moving average of $3.35.
Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. Equities research analysts predict that Abeona Therapeutics will post ($0.73) EPS for the current year.
In related news, Director Todd Wider bought 5,000 shares of the business’s stock in a transaction dated Tuesday, September 20th. The shares were purchased at an average cost of $5.48 per share, with a total value of $27,400.00. Following the completion of the purchase, the director now owns 75,000 shares in the company, valued at approximately $411,000. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 13.00% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in ABEO. BlackRock Fund Advisors boosted its stake in Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock worth $774,000 after buying an additional 23,734 shares in the last quarter. Royce & Associates LP boosted its stake in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares in the last quarter. Geode Capital Management LLC boosted its stake in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares in the last quarter. Finally, Sabby Management LLC boosted its stake in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares in the last quarter. 19.95% of the stock is currently owned by hedge funds and other institutional investors.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.